EVE Health Launches Libbo and Expands Pipeline with $1.3M Capital Raise

Commercial Launch of Libbo and Digital Men’s Health Ecosystem

EVE Health Group (ASX:EVE) has crossed a significant milestone by commencing the commercial launch of Libbo, its oral dissolving film treatment for erectile dysfunction, in Australia. This launch follows the completion of manufacturing and national distribution, marking the transition from development to real-world patient access. Key to this rollout is EVE’s integrated men’s health digital platform, stiffissue.com, which combines patient education, telehealth prescribing partnerships, and pharmacy fulfilment into a seamless, scalable national access model within Australia’s regulated healthcare framework.

The digital ecosystem aims to enhance patient engagement and facilitate earlier treatment access, providing a foundation for future product extensions across related therapeutic areas. This approach aligns with EVE’s strategy to embed digital tools alongside pharmaceutical offerings, potentially differentiating its commercial model in men’s health.

Pipeline Expansion with Novel Reformulated Pharmaceutical Candidates

Beyond Libbo, EVE has materially expanded its reformulated pharmaceutical pipeline during the quarter, completing research and development on multiple candidates targeting sexual health and cardiovascular therapies. New proprietary oral spray formulations include a vardenafil erectile dysfunction spray, a dapoxetine premature ejaculation spray, and a dual-molecule vardenafil plus dapoxetine combination. Additionally, the company advanced a reformulated apixaban program, aimed at improving solubility and delivery for this widely prescribed anticoagulant, with a provisional patent application already lodged.

EVE’s reformulation strategy focuses on established drugs nearing patent expiry, leveraging its proprietary delivery and solubilisation technologies to offer improved onset, convenience, and new intellectual property protection. The company intends to commercialise these candidates through licensing and supply partnerships with pharmaceutical firms possessing established regulatory and distribution capabilities, reflecting a capital-light, partner-led model reminiscent of its previous capital raising efforts.

Strengthening Scientific Advisory and Leadership

In a move to bolster clinical and strategic expertise, EVE appointed Dr Sama Balasubramanian, a specialist in sexual health and men’s medicine, to its Scientific Advisory Board. His experience spans clinical practice, medical education, and health governance, providing independent guidance on product development and therapeutic positioning as Libbo enters commercial rollout.

Leadership changes continued post-quarter with the appointment of Ben Rohr as Chief Executive Officer. Rohr has been central to EVE’s recent operational progress, including pharmaceutical strategy and commercial execution. This transition, which shifts former CEO Damian Wood to focus on regulatory and clinical affairs, aims to sharpen the company’s commercial momentum amid ongoing product launches and pipeline expansion, building on the leadership restructure announced recently ahead of the capital raise.

Financial Position and Capital Raising

EVE completed a $1.3 million placement during the quarter at $0.02 per share, including a $400,000 commitment from a new cornerstone investor with pharmaceutical development and commercialisation expertise. These funds are earmarked to advance reformulated pharmaceutical candidates, intellectual property protection, regulatory activities, and further development targeting global therapeutic markets estimated to exceed US$30 billion annually.

At quarter-end, EVE held $1.75 million in cash, with customer receipts steady at $0.25 million. Operating cash outflows of $369,000 reflect ongoing investment in marketing, research, and staff costs. The company’s financing strategy and cash runway suggest approximately five quarters of funding available at current operating levels.